Renal Flashcards
Degarelix
Hormonal treatment for prostate cancer
GnRH antagonist: Directly blocks the binding of GnRH to its receptor directly
Do not get initial androgen flare like you do with the GnRH agonists (leuprolide and goserelin)
This drug lacks the initial androgen flare that is seen with the agonists
Leuprolide
Decapeptide hormonal treatment for prostate cancer
GnRH normally released in pulsatile fashion, but the synthetic agonists are given so that they simulate a sustained release of GnRH, after 2-4 weeks of treatment, you down regulate the testosterone levels
GnRH agonist: MOA is to desensitize/downregulate the GnRH receptors on the pituitary
Modified to lengthen half-life and minimize break down
Used in combination with androgen receptor antagonists to avoid the androgen flare associated with these drugs
Goserelin
Decapeptide hormonal treatment for prostate cancer
GnRH normally released in pulsatile fashion, but the synthetic agonists are given so that they simulate a sustained release of GnRH, after 2-4 weeks of treatment, you down regulate the testosterone levels
GnRH agonist: MOA is to desensitize/downregulate the GnRH receptors on the pituitary
Modified to lengthen half-life and minimize break down
Used in combination with androgen receptor antagonists to avoid the androgen flare associated with these drugs
Flutamide, Nilutamide, Bicalutamide, Cyproterone, Spironolactone
Hormonal treatment of prostate cancer
Androgen receptor antagonists: Bind to steroid receptor intracellularly and prevent its translocation into the nucleus
Used in conjunction with GnRH agonists
Flutamide: has diarrhea nausea and vomiting for toxicity
Bicalutamide: less side effects and most used
Cyproterone: also has slight agonist activity. Have to watch out for this
Abiraterone
Irreversible inhibitor of 17-hydroxylase and C-17,20-lyase (CYP17) activity that blocks testosterone biosynthesis
Used with prednisone. It is better than ketoconazole
Use if patient isn’t responding well to leuprolide and androgen blocking agents or in conjunction with them
Mitoxanthrone
Used for hormone-refractory prostate cancer
Doxorubicin analog with less cardiotoxicity
Sometimes used with prednisone
Docetaxel and cabazitaxel
Used for hormone-refractory prostate cancer
Inhibits microtubule disassembly
Cabazitaxel used with prednisone, most widely used today
Toxicity is neutropenia and neurotoxicity
Sipuleucel-T (PROVENGE)
Autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic, metastatic, hormone refractory prostate cancer
Toxicity is infusion reactions
Bladder cancer chemotherapy
Intravesicular agents (given as a catheter in the bladder in conjunction with transurethral resection)- bacillus calmette-guerin, thiotepa, mitomycin, valrubicin, agents are very toxic if given systemically** **
Bacillus calmette-guerin: it is an attenuated organism, causes a granulomatous reaction that kills the cancer
Thiotepa: activated by CYP450 and is an alkylator and damages DNA, absorbed a little and causes myelosuppression
Mitomycin: Alkylator that is not absorbed at all
Valrubicin: Synthetic analog of doxirubicin for BCG resistant bladder cancer
MVAC for advanced cases (methotrexate, vinblastine, doxorubicin, cisplatin-more renal damage than carboplatin)
MVAC
Systemic agents for advanced cases of bladder cancer
Methotrexate, vinblastine, doxorubicin, cisplatin
Renal damage from cisplatin is reduced by hydration/saline diuresis, can use carboplatin in combo with paclitaxel in patients with renal dysfunction
Can also use gemcitabine with cisplatin or carboplatin
IL-2
Differs from native IL-2 in that it is not glycosylated, so it is more stable
Stimulates proliferation and activities of tumor-attacking lymphokine-activated killer cells and CTLs
Toxicities: inflammation/capillary leak, hypertension, arrythmias, peripheral edema, nausea, diarrhea, vomitting, and fever
Used to treat patients with cancers that are refractory to conventional treatment, such as renal cell carcinoma and melanoma
Sunitinib
Renal cell carcinoma treatment
Inhibitor of receptor tyrosine kinases (VEGF-R2, PDGF-R, c-KIT, and other tyrosine kinases)
Reduces proliferation and angiogenesis
Resistance is through receptor tyrosine kinase mutation
Toxicity: bleeding, hypertension, proteinuria, thromboembolism, intestinal perforation, and myelosuppression
Sorafenib
Renal cell carcinoma treatment
Oral inhibitor of VEGF-R1,2,3 tyrosine kinases within tumor cells to reduce proliferation and angiogenesis
Toxicity: bleeding, hypertension, proteinuria, thromboembolism, intestinal perforation, and myelosuppression
Bevacizumab
Renal cell carcinoma treatment
Humanized mAb against VEGF
Inhibits interaction with VEGF receptors which inhibits angiogenesis in tumors
Often given with interferon-alpha
Toxicity: CNS hemorrhage, severe hypertension, congestive heart failure, gastric perforation, and proteinuria
Pazopanib
Renal cell carcinoma treatment
Inhibits tyrosine kinase activity of VEGF-R2
Toxicity: bleeding, hypertension, proteinuria, thromboembolism, intestinal perforation, and myelosuppression
Temsirolimus, Everolimus, Sirolimus
Rapamycins
mTOR forms the mTORC1 complex with the FK506-binding protein family, FKBP12. mTORC1 phosphorylates S6 kinase and relieves inhibitory effect of 4EBP on initiation factor elf-4E thereby increasing protein synthesis and metabolism
Antitumor actions result from binding FKBP12 and inhibition of mTORC1
Temsirolimus is metabolized to sirolimus
Inhibit cell-cycle progression and angiogenesis, promote apoptosis
Resistance: mTORC2 can take over for mTORC1 complex
Toxicity is mild: rash, small chance of leukopenia, inhibit CYP450s
Treatment of UTI’s
Main outpatient pathogens are E. coli, then Klebsiella and Proteus, then Staph. saprophyticus
Pseudomonas is rare in outpatient but common in hospital setting
Treat cystitis with TMP-SMX, ciprofloxacin/levofloxacin (resistance is increasing to fluoroquinolones), cefpodoxime proxetil
Treat pyelonephritis with fluoroquinolones (high doses to overcome resistance), treat susceptible strains with TMP-SMX
Treat suspected bacteremia with IV antibiotics (third generation cephaolsporins, ciprofloxacin, gentamycin, aztreonam)
Extremely sick treat with IV cefepime, ciprofloxacin, carbepenem
Mineralocorticoids
Aldosterone is the naturally occurring mineralocorticoid (because it is protected from 11B-HSD2 deactivation)
Increase Na+ reabsorption in distal nephron/collecting duct (mainly through prinicipal cells)
Leads to increase H20 reabsorption, K+ secretion (worry about hypokalemia if we over-do it), H+ secretion, and bicarb generation (can create alkalosis if we secrete too much H+ and generate too much bicarb)
Side effects: HTN, edema via sodium and water retention
Glucocorticoids are more abundant than Mineralocorticoids and bind GR and MR however: 11B-HSD2 oxidizes -OH (Carbon11) to =O (C11) that cannot bind to the mineralocorticoid receptor*** - We can flood this system and the glucocorticoids can eventually bind to the MR and lead to aldosterone-like effects
Component in licorice that inhibits 11B-HSD2 and allows these glucocorticoids to remain capable of binding MR
Fludrocortisone
Binds very well to mineralocorticoid receptor***
Binds POTENTLY to GR and MR
Both a glucocorticoid and a mineralcorticoid
NEVER use as an anti-inflammatory as it will cause severe edema, water-retention, HTN
Use when Pts cannot make aldosterone themselves
Triamcinolone
A glucocorticoid that has ABSOLUTELY NO activity at the mineralocorticoid receptor (thus no aldosterone-like activity)
Useful treatment if you need to switch a patient to an anti-inflammatory without water retention/due to their HTN with the other glucocorticoids (such as prednisone, which has a slight affinity for the MR)
Mineralocorticoid Receptor Antagonists
Aldosterone antagonists***
Spironolactone (gynocomastia, impotence for this one too) - Eplerenone
Can cause hyperkalemia and metabolic acidosis as they are no longer allowing K+ secretion, H+ secretion, or HCO3- creation
Can treat aldosterone or cortisol excess
Calcitriol
People who are in renal failure do not make active vitamin D (Calcitriol, AKA 1,25-dihydroxy-cholecalciferol)
Hyperphosphatemic and Hypocalcemic- PTH is released because of hypocalcemia which leads to bone resorption, calcium reabsorption in kidney, and phosphate excretion in kidney
However, if the kidney is damaged we don’t see this but we end up seeing secondary hyperparathyroidism - Will see renal osteodystrophy with this excessive resorption***
Calcitriol is already active and will help Ca2+ absorption in the gut, increase Ca2+ in the blood, and STOP PTH production/bone resorption
Don’t give ergocalciferol or other calcitriol analogs lacking the 1-hydroxylation
DHT - Dihydrotachysterol
Synthetic Vitamin D
No 1-OH needed for activation so no renal activation needed to be active Vitamin D
Could also give 1-apha-hydroxycalciferol, but this one needs liver function to be activated